Stock A000100 YUHAN CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Yuhan Corporation

Equities

A000100

KR7000100008

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-09 pm EDT 		5-day change 1st Jan Change
78,400 KRW -4.16% Intraday chart for Yuhan Corporation +13.95% +13.95%
May. 16 Yuhan Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,952,225 4,693,094 4,261,559 4,093,463 5,152,134 5,865,507 - -
Enterprise Value (EV) 2 2,626 4,368 3,950 3,870 5,056 5,839 5,540 5,319
P/E ratio 75.2 x 25.5 x 41.5 x 40.7 x 37.9 x 40.9 x 29.5 x 24.6 x
Yield 0.85% 2.66% 0.64% 0.7% 0.58% 0.53% 0.54% 0.57%
Capitalization / Revenue 1.99 x 2.9 x 2.52 x 2.31 x 2.77 x 2.76 x 2.56 x 2.51 x
EV / Revenue 1.77 x 2.7 x 2.34 x 2.18 x 2.72 x 2.75 x 2.42 x 2.28 x
EV / EBITDA 36.9 x 30.3 x 39 x 49 x 49.8 x 32.6 x 23.4 x 19.3 x
EV / FCF 114 x -193 x 74.7 x 93.9 x -291 x 44.8 x 30.7 x 22.1 x
FCF Yield 0.88% -0.52% 1.34% 1.07% -0.34% 2.23% 3.26% 4.52%
Price to Book 1.67 x 2.5 x 1.96 x 1.91 x 2.36 x 2.78 x 2.61 x 2.43 x
Nbr of stocks (in thousands) 75,773 72,231 75,593 75,139 74,979 75,000 - -
Reference price 3 38,914 64,874 56,327 54,476 68,800 78,400 78,400 78,400
Announcement Date 2/27/20 2/24/21 2/16/22 2/23/23 2/6/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,480 1,620 1,688 1,776 1,859 2,123 2,287 2,337
EBITDA 1 71.19 144 101.3 79.05 101.4 179.1 236.4 275.9
EBIT 1 12.54 84.26 48.6 36.03 56.78 144.7 188 220.9
Operating Margin 0.85% 5.2% 2.88% 2.03% 3.05% 6.82% 8.22% 9.45%
Earnings before Tax (EBT) 1 54.92 239.9 126.1 94.93 142.5 176.3 242.1 292.5
Net income 1 36.61 192.8 102.6 95.14 142.5 146.5 204.7 250.9
Net margin 2.47% 11.9% 6.08% 5.36% 7.67% 6.9% 8.95% 10.73%
EPS 2 517.1 2,542 1,357 1,339 1,815 1,918 2,656 3,183
Free Cash Flow 3 23,000 -22,623 52,849 41,234 -17,352 130,199 180,322 240,188
FCF margin 1,553.71% -1,396.58% 3,131.24% 2,321.92% -933.39% 6,133.09% 7,884.03% 10,277.79%
FCF Conversion (EBITDA) 32,307.01% - 52,188.42% 52,163.18% - 72,681.57% 76,276.07% 87,063.58%
FCF Conversion (Net income) 62,821.54% - 51,518.9% 43,338.05% - 88,853.92% 88,072.9% 95,747.72%
Dividend per Share 2 329.1 1,728 362.8 381.0 400.0 417.9 425.4 443.9
Announcement Date 2/27/20 2/24/21 2/16/22 2/23/23 2/6/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 424 410.9 483 431.5 450.5 443 495.7 483.1 437.2 444.6 524.8 523.5 554.7
EBITDA 1 - - 27.65 6.006 28.34 - 38.25 11.93 17.95 - 53 81 38
EBIT 1 4.752 6.102 16.94 -4.538 17.53 22.63 27.08 0.8833 5.95 0.5771 28.18 24.62 53.3
Operating Margin 1.12% 1.49% 3.51% -1.05% 3.89% 5.11% 5.46% 0.18% 1.36% 0.13% 5.37% 4.7% 9.61%
Earnings before Tax (EBT) 1 19.57 28.32 43.43 21.78 1.398 35.81 13.74 19.31 65.68 14.94 42.5 - -
Net income 1 17.13 15.93 34.08 7.526 37.6 22.24 8.678 19.59 85.58 12.71 36.06 46.05 42.82
Net margin 4.04% 3.88% 7.06% 1.74% 8.35% 5.02% 1.75% 4.06% 19.58% 2.86% 6.87% 8.8% 7.72%
EPS - - - - - 296.2 - - - - - - -
Dividend per Share - - - - - - - - - - - - -
Announcement Date 2/16/22 4/29/22 7/28/22 11/14/22 2/23/23 5/15/23 7/28/23 11/14/23 2/6/24 5/16/24 - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 326 326 312 223 96 27 326 546
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 2 23,000 -22,623 52,849 41,234 -17,352 130,199 180,322 240,188
ROE (net income / shareholders' equity) 2.22% 10.9% 5.24% 4.59% 6.92% 7.28% 9.09% 9.92%
ROA (Net income/ Total Assets) 1.71% 8.44% 4.22% 3.85% 5.15% 4.82% 6.36% 6.97%
Assets 1 2,146 2,283 2,429 2,468 2,769 3,041 3,220 3,598
Book Value Per Share 3 23,241 25,984 28,703 28,542 29,194 28,182 30,093 32,292
Cash Flow per Share 3 928.0 2,137 1,468 1,401 1,923 2,714 3,177 3,587
Capex 1 42.8 51.5 46.2 58.3 161 83.8 64.4 65.6
Capex / Sales 2.89% 3.18% 2.73% 3.28% 8.69% 3.95% 2.81% 2.81%
Announcement Date 2/27/20 2/24/21 2/16/22 2/23/23 2/6/24 - - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Yuhan Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
78,400 KRW
Average target price
89,218 KRW
Spread / Average Target
+13.80%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
YUHAN CORPORATION Stock Yuhan Corporation
+13.95% 4.44B
MERCK KGAA Stock Merck KGaA
+19.29% 80.5B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+15.08% 9.15B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-18.33% 4.9B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.39% 4.49B
INDIVIOR PLC Stock Indivior PLC
+10.89% 2.19B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-28.40% 2.13B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+15.93% 2.1B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-43.17% 1.78B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A000100 Stock
  4. Financials Yuhan Corporation